CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CTO Raymond Woo sold 4,887 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $26.96, for a total transaction of $131,753.52. Following the completion of the transaction, the chief technology officer owned 203,118 shares in the company, valued at approximately $5,476,061.28. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Raymond Woo also recently made the following trade(s):
- On Thursday, October 1st, Raymond Woo sold 4,887 shares of CeriBell stock. The shares were sold at an average price of $24.38, for a total value of $119,145.06.
- On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total value of $118,900.71.
- On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $47,535.58.
CeriBell Stock Performance
Shares of CBLL traded down $0.78 during mid-day trading on Wednesday, hitting $27.50. 683,154 shares of the company’s stock were exchanged, compared to its average volume of 367,620. CeriBell, Inc. has a 52 week low of $10.94 and a 52 week high of $28.89. The stock’s 50-day simple moving average is $25.06 and its 200-day simple moving average is $20.85. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -15.63 and a beta of 0.86. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.
CeriBell (NASDAQ:CBLL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). The company had revenue of $29.34 million for the quarter, compared to the consensus estimate of $29.18 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. On average, equities research analysts expect that CeriBell, Inc. will post -1.96 EPS for the current year.
Analyst Ratings Changes
CBLL has been the subject of several recent analyst reports. TD Cowen upped their price objective on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Canaccord Genuity Group increased their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, BTIG Research reissued a “buy” rating on shares of CeriBell in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CeriBell has a consensus rating of “Moderate Buy” and an average price target of $27.00.
Check Out Our Latest Stock Report on CBLL
Key Headlines Impacting CeriBell
Here are the key news stories impacting CeriBell this week:
- Positive Sentiment: CeriBell commercially launched a delirium-monitoring solution, expanding its point-of-care brain-monitoring platform and adding a new potential source of revenue. Article: Ceribell Expands Its Point-of-Care Brain Monitoring Platform
- Positive Sentiment: Third-quarter revenue was $29.34 million, slightly ahead of analysts’ $29.18 million estimate. Zacks reported a loss of $0.48 per share versus its $0.50 consensus loss estimate. Article: CeriBell Reports Q3 Loss, Tops Revenue Estimates
- Negative Sentiment: The company reported a $21 million quarterly loss, with new-launch expenses contributing to the higher loss. Its reported EPS of -$0.55 missed the consensus estimate of -$0.51, while the per-share loss worsened from $0.37 a year earlier. Article: CeriBell Posts Higher Q3 Loss With New Launch Expenses
- Negative Sentiment: CTO Raymond Woo sold 4,887 shares for about $132,000. The sale reduced his holdings by 2.35%, though he retained 203,118 shares. SEC insider transaction filing
Institutional Trading of CeriBell
Institutional investors and hedge funds have recently modified their holdings of the business. Strs Ohio bought a new position in CeriBell in the first quarter valued at about $27,000. Legal & General Group Plc bought a new position in shares of CeriBell in the second quarter worth about $53,000. State of Wyoming bought a new position in shares of CeriBell in the first quarter worth about $62,000. Quantbot Technologies LP acquired a new stake in shares of CeriBell in the 2nd quarter valued at approximately $112,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of CeriBell in the 1st quarter valued at approximately $341,000.
About CeriBell
CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.
The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.
Featured Stories
- Five stocks we like better than CeriBell
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
- Bloom Energy: The Off-Grid Answer to AI’s Power Drain
- Space Race 2.0: Intuitive Machines Secures Another NASA Contract
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
